RESTASIS

Font Size : Normal | Large

Not a health care professional?
Please visit our site for patients

A 30-Day Supply of RESTASIS® Is 2 Trays

Dosage

RESTASIS Prescription Eyedrops

The approved dosage for RESTASIS® Ophthalmic Emulsion is 1 drop in each eye in the morning and 1 drop in each eye in the evening. Vials should be discarded after each use. Therefore, a patient will need 2 vials a day. When used as approved, 2 trays (60 vials) is the recommended 30-day supply of RESTASIS®.

The Cost to Patients

Approximately 97.9% of your patients with commercial insurance have plans that cover most of the cost of their RESTASIS® Ophthalmic Emulsion prescriptions.1 On average, a patient's co-pay for a RESTASIS® prescription ranges from $20 to $50 depending on coverage.1 Each co-pay covers a 30-day supply (2 trays). To help your patients save money, start them off with the RESTASIS® Smart Start Program, and encourage your patients to use other money-saving offers, such as a $20 rebate, to help offset the cost of their prescriptions.

Reference:

  1. Data on file, Allergan, Inc.

RESTASIS® Ophthalmic Emulsion is indicated to increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca. Increased tear production was not seen in patients currently taking topical anti-inflammatory drugs or using punctal plugs.

Important Safety Information:

RESTASIS® is contraindicated in patients with active ocular infections and has not been studied in patients with a history of herpes keratitis.

The most common adverse event was ocular burning (upon instillation) – 17%. Other events reported in 1% to 5% of patients included conjunctival hyperemia, discharge, epiphora, eye pain, foreign body sensation, pruritus, stinging, and visual disturbance (most often blurring).

Please see full prescribing information for RESTASIS® (cyclosporine ophthalmic emulsion) 0.05%.


Allergan, Inc.

© 2008 Allergan, Inc. All rights reserved. | Privacy Statement | FAQs | Terms of Use | Site Map | Contact Us
This information is intended for residents of the United States. ® and ™ marks owned by Allergan, Inc.